Search Results
Sep 10, 2026, 03:34 ET Elkem ASA - Second quarter and half year report 2026 (correction)
https://mb.cision.com/Public/16930/4394254/874cb57406a5fe49.pdfElkem ASA - 2Q-2026 - Report Corr
More news about: Elkem
Sep 10, 2026, 03:32 ET Elkem ASA - Second quarter and half year report 2026 (correction)
https://mb.cision.com/Public/16930/4394254/874cb57406a5fe49.pdfElkem ASA - 2Q-2026 - Report Corr
More news about: Elkem
Sep 08, 2026, 07:30 ET Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
pembrolizumab delivers a 48.3% cORR and 72.4% of patients remain progression free at 6 months, compared with 26.5% and 42.8% for pembrolizumab aloneResults are most pronounced in HPV+ patients, with cORR (80.0% vs 33.3%), CR rate
More news about: Inhibrx Biosciences, Inc.
Aug 20, 2026, 08:00 ET Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
follow-up. Specifically, at a median follow-up of 38.8 months in the J201 study, treatment with safusidenib showed a confirmed objective response rate (cORR) of 51.9%, with median progression-free survival (PFS) not yet reached and a 36-month PFS rate of 79.1%, and only one patient who had previously responded
More news about: Nuvation Bio Inc.
Aug 06, 2026, 07:30 ET Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Cancer Research (AACR) Annual Meeting 2026. Notably, in the pooled TKI-naïve population, IBTROZI demonstrated robust confirmed overall response rates (cORR), mDOR and mPFS in TKI-naïve patients. Updated results from the TRUST-I study were also simultaneously published in the
More news about: Nuvation Bio, Inc.
Aug 05, 2026, 20:00 ET Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China
link]Among patients treated with IBI363 in combination with bevacizumab (n=73), the overall confirmed objective response rate (cORR) was 15.1%, and the disease control rate (DCR) was 61.6%. With a median follow-up of 9.9 months, the progression-free survival (PFS) reached 4.7 months.
More news about: Innovent Biologics
Aug 04, 2026, 08:03 ET Kohler Expands Heated BubbleMassage Portfolio with Ceric and Evok Freestanding Baths
reflects our continued focus on delivering meaningful solutions that integrate naturally into daily life and enhance wellness within," said Michael Corr, Sr. Brand Manager - Kohler Health & Wellness. "With Ceric and Evok, we're pairing Kohler's elevated bath design with proven hydrotherapy performance
More news about: Kohler Co.
Aug 04, 2026, 08:00 ET Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
advanced ROS1+ NSCLC in China (N=173) and globally (N=189), respectively. The primary endpoint of both studies is confirmed objective response rate (cORR) as assessed by an independent review committee. TRUST-IV (
More news about: Nuvation Bio Inc.
Jul 09, 2026, 05:28 ET InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation
population.Key findings published in this paper:High Response Rates: Of the 33 enrolled patients, 31 were evaluable. The cORR was 82% (27/33) across all enrolled patients and 87% (27/31) among evaluable patients. And tumor shrinkage was observed in all evaluable patients, even
More news about: InxMed Co., Ltd
Jun 29, 2026, 08:00 ET Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
advanced ROS1+ NSCLC in China (N=173) and globally (N=189), respectively. The primary endpoint of both studies is confirmed objective response rate (cORR) as assessed by an independent review committee. TRUST-IV (
More news about: Nuvation Bio Inc.
Jun 18, 2026, 11:00 ET Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress
platinum-based doublet chemotherapy plus immune checkpoint inhibitors.Among the 53 patients evaluable for efficacy, the confirmed objective response rate (cORR) and disease control rate (DCR) were 32.08% and 81.13%, respectively, with 1 complete response (1.87%) and 17 partial responses (30.19%). Median progression-free
More news about: Mabwell
Jun 17, 2026, 15:01 ET Lakes, Lifestyles & Listings TV Series Spotlights Franksville Real Estate and Lifestyle on REAL Shows Network
Locally hosted series led by Emily Corr highlights the people, neighborhoods, and businesses that define Franksville and the broader Wisconsin lake country lifestyle.FRANKSVILLE, Wis., June 17, 2026 /PRNewswire/ -- REAL
More news about: REAL Shows Network
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
NSCLC with PD-L1 negative or low expression. The 3→1.5 mg/kg dose group (n=22) showed ORR of 86.4%, confirmed ORR (cORR) of 81.8% (95% CI: 59.7-94.8) and DCR of 100%The second stage of the PoC study is ongoing in head-to-head comparison vs. pembrolizumab
More news about: Innovent Biologics
May 27, 2026, 08:00 ET Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
advanced ROS1+ NSCLC in China (N=173) and globally (N=189), respectively. The primary endpoint of both studies is confirmed objective response rate (cORR) as assessed by an independent review committee. TRUST-IV (
More news about: Nuvation Bio Inc.
May 22, 2026, 00:58 ET 2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in Combination with Chemotherapy as First-line Treatment for Advanced NSCLC, Showing Encouraging Efficacy Signals and Favorable Safety
signals were observed in the 3→1.5 mg/kg groups with ongoing follow-up. For the 1.5mg/kg (N = 19) and 3 mg/kg cohorts (N = 21), ORR was 57.9% (cORR: 42.1%) and 66.7% (cORR: 57.1%), respectively. For NSCLC patients with negative or low PD‑L1 expression, the benefit from current immunotherapies is
More news about: Innovent Biologics
May 11, 2026, 08:00 ET Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population, the INBRX-106 + pembrolizumab combination achieved a cORR of 44.0% versus 21.4% with pembrolizumab alone, representing a 22.6% absolute increase in cORR.Superior depth of response:
More news about: Inhibrx Biosciences, Inc.
May 06, 2026, 08:00 ET Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer
advanced ROS1+ NSCLC in China (N=173) and globally (N=189), respectively. The primary endpoint of both studies is confirmed objective response rate (cORR) as assessed by an independent review committee. TRUST-IV (
More news about: Nuvation Bio Inc.
May 04, 2026, 16:10 ET Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
analysis showed a cORR of 89.8%, a mDOR of 49.7 months, a mPFS of 46.1 months and an intracranial response rate of 76.5% in patients with brain metastases (n=17). Median overall survival (OS) was not yet reached.For TKI-pretreated patients (n=113): the analysis showed a cORR of 55.8%, a mDOR
More news about: Nuvation Bio Inc.
Apr 27, 2026, 08:00 ET Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers
advanced ROS1+ NSCLC in China (N=173) and globally (N=189), respectively. The primary endpoint of both studies is confirmed objective response rate (cORR) as assessed by an independent review committee. TRUST-IV (
More news about: Nuvation Bio Inc.
Apr 22, 2026, 12:20 ET La Semana de la Seguridad en la Construcción 2026 promueve "Recognize, Respond, Respect" (reconocer, responder y respetar) para mejorar la salud y la seguridad del sector
BMWC, Brasfield & Gorrie, Brown and Caldwell, Caddell Construction, CDM Investment Group, CIANBRO, Clark Construction Group, Colony Hardware, Crown Corr, Doka USA, Ltd., Donley's, DPR Construction, E-J Electric Installation Co., EC Electric, Eldeco Inc., EPI Power, Fessler & Bowman, Fluor, Forgen,
More news about: Construction Safety Week
Apr 21, 2026, 18:50 ET /U P D A T E -- Nuvation Bio Inc./
the analysis showed a cORR of 89.8%, a median DOR of 49.7 months, a median PFS of 46.1 months and an intracranial response rate of 76.5% in patients with brain metastases (n=17). Median OS was not yet reached.For TKI-pretreated patients (n=113): the analysis showed a cORR of 55.8%, a median DOR
More news about: Nuvation Bio Inc.
Apr 21, 2026, 13:56 ET Construction Safety Week 2026 Promotes "Recognize, Respond, Respect" to Elevate Industry Health & Safety
BMWC, Brasfield & Gorrie, Brown and Caldwell, Caddell Construction, CDM Investment Group, CIANBRO, Clark Construction Group, Colony Hardware, Crown Corr, Doka USA, Ltd., Donley's, DPR Construction, E-J Electric Installation Co., EC Electric, Eldeco Inc., EPI Power, Fessler & Bowman, Fluor, Forgen,
More news about: Construction Safety Week
Apr 21, 2026, 13:48 ET Construction Safety Week 2026 Promotes "Recognize, Respond, Respect" to Elevate Industry Health & Safety
BMWC, Brasfield & Gorrie, Brown and Caldwell, Caddell Construction, CDM Investment Group, CIANBRO, Clark Construction Group, Colony Hardware, Crown Corr, Doka USA, Ltd., Donley's, DPR Construction, E-J Electric Installation Co., EC Electric, Eldeco Inc., EPI Power, Fessler & Bowman, Fluor, Forgen,
More news about: Construction Safety Week
Mar 26, 2026, 16:05 ET Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
advanced ROS1+ NSCLC in China (N=173) and globally (N=189), respectively. The primary endpoint of both studies is confirmed objective response rate (cORR) as assessed by an independent review committee. TRUST-IV (
More news about: Nuvation Bio Inc.; Eisai Co., Ltd
Mar 24, 2026, 03:43 ET DualityBio (9606.HK) Announces 2025 Annual Results
("uORR") of 43.3%, a Confirmed Objective Response Rate ("cORR") of 33.3%, a Disease Control Rate ("DCR") of 86.7%, and a median Progression-Free Survival ("mPFS") of 7.0 months; in Platinum-Resistant Ovarian Cancer ("PROC") patients (n=12), the cORR was 58.3%, DCR was 75.0%, and mPFS was 8.2 months. The
More news about: Duality Biotherapeutics, Inc.